98 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Heart & Lung Audio PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

    Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

    Visit https://www.peervoice.com/URC860 to view the entire programme with slides. After completing “Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered”, participants will be able to: Evaluate how biologic therapies fit into the treatment paradigm for patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Use patient and disease characteristics to identify patients who may benefit from biologic therapy; and Apply practical strategies for monitoring and managing patients with CRSwNP who are receiving biologic therapy.

    • 21 min
    Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022

    Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022

    Visit https://www.peervoice.com/GHN860 to view the entire programme with slides. After completing “Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022”, participants will be able to: Describe emerging data for targeted therapeutic strategies for management of patients with advanced non–small-cell lung cancer (NSCLC) and actionable mutations; Evaluate how these data add to current knowledge of the management of biomarker-positive advanced NSCLC; and Discuss the clinical implications of these data in the context of current advanced NSCLC treatment paradigms.

    • 23 min
    Javed Butler, MD, MPH, MBA - Changing the Patient Journey Across the Spectrum of Heart Failure

    Javed Butler, MD, MPH, MBA - Changing the Patient Journey Across the Spectrum of Heart Failure

    Visit https://www.peervoice.com/GXR860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Changing the Patient Journey Across the Spectrum of Heart Failure”, participants will be able to: Recognise the different pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF); Summarise how SGLT2 inhibitors are changing the treatment paradigm for HFpEF and HFrEF; and Apply updated strategies to management of patients with HFpEF and HFrEF, with the goal of improving outcomes.

    • 22 min
    Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

    Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

    Visit https://www.peervoice.com/YUS860 to view the entire programme with slides. After completing “Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice”, participants will be able to: Explain the rationale for targeting TROP2 in patients with advanced non–small-cell lung cancer (NSCLC); Assess current clinical data for TROP2-directed antibody-drug conjugates (ADCs) in the management of advanced NSCLC that has progressed on current standards of care; and Formulate optimal, evidence-based treatment plans that maximise long-term outcomes for patients with advanced NSCLC.

    • 24 min
    Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

    Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

    Visit https://www.peervoice.com/HGH860 to view the entire programme with slides. After completing “Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC”, participants will be able to: Apply current evidence-based treatment guidelines in patients with molecular biomarker–positive non–small-cell lung cancer (NSCLC); Propose personalised treatment plans for patients with molecular biomarker–positive NSCLC; and Identify key clinical challenges encountered in the treatment of NSCLC, including next steps in patients without targetable driver mutations.

    • 27 min
    Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC

    Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC

    Visit https://www.peervoice.com/WPN860 to view the entire programme with slides. After completing “Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC”, participants will be able to: Discuss the rationale for adjuvant therapy in the management of patients with early-stage, EGFR-mutant non–small-cell lung cancer (NSCLC); Translate current evidence for EGFR TKIs in the adjuvant setting into optimal treatment plans for patients with early-stage, EGFR-mutant NSCLC; and Identify patient and disease factors that can help guide treatment decision-making in the adjuvant setting.

    • 24 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Hidden Brain
Alie Ward
Sam Harris
CBS News Radio
Neil deGrasse Tyson
Mike Carruthers / OmniCast Media / Cumulus Podcast Network

More by PeerVoice

PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice